Dr. Galsky on the HCRN GU14-182 Study Results in Urothelial Cancer
August 6th 2019Matthew D. Galsky, MD, director, Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai Hospital, discusses results from the HCRN GU14-182 study, which examined maintenance pembrolizumab versus placebo in patients with metastatic urothelial cancer.
Read More
Checkpoint Inhibitors Herald a New Era for Treating Urothelial Cancer
November 7th 2017Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.
Read More
Dr. Galsky on the Role of Ipilimumab in Bladder Cancer
December 5th 2013Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses the role of ipilimumab in bladder cancer.
Read More